Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

More to the RAS Story: KRASG12C Inhibition, Resistance Mechanisms, and Moving Beyond KRASG12C
Caressa Lietman, Melissa L. Johnson, Frank McCormick, et al.
American Society of Clinical Oncology Educational Book (2022), Iss. 42, pp. 205-217
Open Access | Times Cited: 32

Showing 1-25 of 32 citing articles:

Molecular targeted therapy for anticancer treatment
Hye‐Young Min, Ho‐Young Lee
Experimental & Molecular Medicine (2022) Vol. 54, Iss. 10, pp. 1670-1694
Open Access | Times Cited: 240
Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers
Jingjing Jiang, Lingyan Jiang, Benjamin J. Maldonato, et al.
Cancer Discovery (2024) Vol. 14, Iss. 6, pp. 994-1017
Open Access | Times Cited: 74
Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer
Urszula N. Wasko, Jingjing Jiang, Tanner C. Dalton, et al.
Nature (2024) Vol. 629, Iss. 8013, pp. 927-936
Open Access | Times Cited: 55
Direct and selective pharmacological disruption of the YAP–TEAD interface by IAG933 inhibits Hippo-dependent and RAS–MAPK-altered cancers
Emilie A. Chapeau, Laurent Sansregret, Giorgio Giacomo Galli, et al.
Nature Cancer (2024) Vol. 5, Iss. 7, pp. 1102-1120
Open Access | Times Cited: 33
The current landscape of using direct inhibitors to target KRASG12C-mutated NSCLC
Firas Batrash, Mahmoud Kutmah, Jun Zhang
Experimental Hematology and Oncology (2023) Vol. 12, Iss. 1
Open Access | Times Cited: 22
Targeting KRASG12C in Non-Small-Cell Lung Cancer: Current Standards and Developments
Javier Torres-Jiménez, Javier Baena Espinar, Helena Bote de Cabo, et al.
Drugs (2024) Vol. 84, Iss. 5, pp. 527-548
Closed Access | Times Cited: 6
KRASG12C mutant lung adenocarcinoma: unique biology, novel therapies and new challenges
Judit Moldvay, József Tı́már
Pathology & Oncology Research (2024) Vol. 29
Open Access | Times Cited: 5
D3S-001, a KRAS G12C Inhibitor with Rapid Target Engagement Kinetics, Overcomes Nucleotide Cycling, and Demonstrates Robust Preclinical and Clinical Activities
Jing Zhang, Sun Min Lim, Mi Ra Yu, et al.
Cancer Discovery (2024) Vol. 14, Iss. 9, pp. 1675-1698
Open Access | Times Cited: 5
The continually evolving landscape of novel therapies in oncogene-driven advanced non-small-cell lung cancer
Barbara Melosky, Rosalyn A. Juergens, Shantanu Banerji, et al.
Therapeutic Advances in Medical Oncology (2025) Vol. 17
Open Access
Artificial intelligence across oncology specialties: current applications and emerging tools
John Kang, Kyle Lafata, Ellen Kim, et al.
BMJ Oncology (2024) Vol. 3, Iss. 1, pp. e000134-e000134
Open Access | Times Cited: 4
Regulatory approval of clinical trials: is it time to reinvent the wheel?
Mansoor N. Saleh, Karishma Sharma, Aisleen Shamshudin, et al.
BMJ Global Health (2024) Vol. 9, Iss. 1, pp. e013727-e013727
Open Access | Times Cited: 4
Exploring the Genetic Orchestra of Cancer: The Interplay Between Oncogenes and Tumor-Suppressor Genes
S. P. Singh, Rakesh Bhaskar, Shampa Ghosh, et al.
Cancers (2025) Vol. 17, Iss. 7, pp. 1082-1082
Open Access
Discovering and Targeting Dynamic Drugging Pockets of Oncogenic Proteins: The Role of Magnesium in Conformational Changes of the G12D Mutated Kirsten Rat Sarcoma-Guanosine Diphosphate Complex
Zheyao Hu, Jordi Martı́
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 22, pp. 13865-13865
Open Access | Times Cited: 16
Effect of exercise interventions on hospital length of stay and admissions during cancer treatment: a systematic review and meta-analysis
David Mizrahi, Jonathan Lai, Hayley Wareing, et al.
British Journal of Sports Medicine (2023) Vol. 58, Iss. 2, pp. 97-109
Open Access | Times Cited: 9
The role of molecular testing in pancreatic cancer
David B. Zhen, Rachael A. Safyan, Eric Q. Konick, et al.
Therapeutic Advances in Gastroenterology (2023) Vol. 16
Open Access | Times Cited: 7
Gluing GAP to RAS Mutants: A New Approach to an Old Problem in Cancer Drug Development
Ivan Ranđelović, Kinga Nyíri, Gergely Koppány, et al.
International Journal of Molecular Sciences (2024) Vol. 25, Iss. 5, pp. 2572-2572
Open Access | Times Cited: 2
Molecular Landscape and Therapeutic Strategies against Colorectal Cancer
Aakash Patel, Pat Gulhati
Cancers (2024) Vol. 16, Iss. 8, pp. 1551-1551
Open Access | Times Cited: 2
Resistance to KRAS inhibition in advanced non-small cell lung cancer
Katherina Bernadette Sreter, Maria Joana Catarata, Maximilian von Laffert, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 2
Discovery of BBO-8520, a first-in-class direct and covalent dual inhibitor of GTP-bound (ON) and GDP-bound (OFF) KRASG12C
Anna E. Maciag, James P. Stice, Bin Wang, et al.
Cancer Discovery (2024) Vol. 15, Iss. 3, pp. 578-594
Open Access | Times Cited: 2
Tumor-selective effects of active RAS inhibition in pancreatic ductal adenocarcinoma
Urszula N. Wasko, Jingjing Jiang, Alvaro Curiel-Garcia, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2023)
Open Access | Times Cited: 6
Endogenous oncogenic KRAS expression increases cell proliferation and motility in near-diploid hTERT RPE-1 cells
Naushin L. Hindul, Lauren R. Abbott, Sumaya M D Adan, et al.
Journal of Biological Chemistry (2024) Vol. 300, Iss. 6, pp. 107409-107409
Open Access | Times Cited: 1
KRASG12C‐inhibitor‐based combination therapies for pancreatic cancer: insights from drug screening
Constanza Tapia Contreras, Jonas Dominik Falke, Dana‐Magdalena Seifert, et al.
Molecular Oncology (2024)
Open Access | Times Cited: 1
The farnesyl transferase inhibitor KO-2806 re-sensitizes relapsing tumors to RAS inhibition
Hetika Vora Patel, Alison Smith, Stacia Chan, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 1
With a little help from my T friends: T cells increase efficacy of KRAS (G12D) inhibitors
Sara Mainardi
Cell Reports Medicine (2023) Vol. 4, Iss. 2, pp. 100950-100950
Open Access | Times Cited: 3
FBXL16 promotes cell growth and drug resistance in lung adenocarcinomas with KRAS mutation by stabilizing IRS1 and upregulating IRS1/AKT signaling
Marion Morel, Weiwen Long
Molecular Oncology (2023) Vol. 18, Iss. 3, pp. 762-777
Open Access | Times Cited: 3
Page 1 - Next Page

Scroll to top